|
Delayed
OTC Markets
09:23:32 02/07/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 1.690 USD | +0.90% |
|
-.--% | +14.19% |
| 02/07 | Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences | MT |
| 30/06 | Hanmi Pharm. Co., Ltd. completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc.. | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
EBT: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 (USD) | 2018 (USD) | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Net Income | -6.54Cr | -4.18Cr | -5.12Cr | -2.54Cr | -2.55Cr | |||||
D&A | 6L | 5L | 5L | 4L | 22T | |||||
EBT | -6.54Cr | -4.18Cr | -5.12Cr | -2.54Cr | -2.55Cr | |||||
CAPEX | -2L | -24T | -29T | -5T | - | |||||
Interest Expense | - | - | - | -2L | -8L | |||||
Total Assets | 8.25Cr | 5.1Cr | 1.3Cr | 1.01Cr | 1Cr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 (USD) | 2018 (USD) | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
EBT | -6.54Cr | -4.18Cr | -5.12Cr | -2.54Cr | -2.55Cr | |||||
Net Income | -6.54Cr | -4.18Cr | -5.12Cr | -2.54Cr | -2.55Cr | |||||
CAPEX | -2L | -24T | -29T | -5T | - | |||||
D&A | 6L | 5L | 5L | 4L | 22T | |||||
Interest Expense | - | - | - | -2L | -8L | |||||
Total Assets | 8.25Cr | 5.1Cr | 1.3Cr | 1.01Cr | 1Cr |
- Stock Market
- Stocks
- APS Stock
- APTO Stock
- Financials Aptose Biosciences Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
